These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

526 related articles for article (PubMed ID: 28249824)

  • 1. A new construct of antibody-drug conjugates for treatment of B-cell non-Hodgkin's lymphomas.
    Zhang L; Fang Y; Kopeček J; Yang J
    Eur J Pharm Sci; 2017 May; 103():36-46. PubMed ID: 28249824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-Lymphoma Efficacy Comparison of Anti-Cd20 Monoclonal Antibody-Targeted and Non-Targeted Star-Shaped Polymer-Prodrug Conjugates.
    Lidický O; Janoušková O; Strohalm J; Alam M; Klener P; Etrych T
    Molecules; 2015 Nov; 20(11):19849-64. PubMed ID: 26556320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FRET-trackable biodegradable HPMA copolymer-epirubicin conjugates for ovarian carcinoma therapy.
    Yang J; Zhang R; Radford DC; Kopeček J
    J Control Release; 2015 Nov; 218():36-44. PubMed ID: 26410808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indium-based and iodine-based labeling of HPMA copolymer-epirubicin conjugates: Impact of structure on the in vivo fate.
    Zhang L; Zhang R; Yang J; Wang J; Kopeček J
    J Control Release; 2016 Aug; 235():306-318. PubMed ID: 27266365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of N-(2-hydroxypropyl) methacrylamide copolymer-Mesochlorine e6 and adriamycin conjugates in combination treatments.
    Shiah JG; Sun Y; Peterson CM; Straight RC; Kopecek J
    Clin Cancer Res; 2000 Mar; 6(3):1008-15. PubMed ID: 10741728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of Rituximab-resistant B-cell lymphoma with a novel multi-component anti-CD20 mAb nanocluster.
    Li H; Zhang G; Jiang C; Zhang F; Ke C; Zhao H; Sun Y; Zhao M; Chen D; Zhu X; Zhang L; Li B; Dai J; Li W
    Oncotarget; 2015 Sep; 6(27):24192-204. PubMed ID: 26284588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Two-Step Pretargeted Nanotherapy for CD20 Crosslinking May Achieve Superior Anti-Lymphoma Efficacy to Rituximab.
    Chu TW; Zhang R; Yang J; Chao MP; Shami PJ; Kopeček J
    Theranostics; 2015; 5(8):834-46. PubMed ID: 26000056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sortase A-Generated Highly Potent Anti-CD20-MMAE Conjugates for Efficient Elimination of B-Lineage Lymphomas.
    Pan L; Zhao W; Lai J; Ding D; Zhang Q; Yang X; Huang M; Jin S; Xu Y; Zeng S; Chou JJ; Chen S
    Small; 2017 Feb; 13(6):. PubMed ID: 27873460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel reduction-sensitive micellar nanoparticles assembled from Rituximab-doxorubicin conjugates as smart and intuitive drug delivery systems for the treatment of non-Hodgkin's lymphoma.
    Yin H; Meng T; Shu L; Mao M; Zhou L; Chen H; Song D
    Chem Biol Drug Des; 2017 Nov; 90(5):892-899. PubMed ID: 28440948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates.
    Law CL; Cerveny CG; Gordon KA; Klussman K; Mixan BJ; Chace DF; Meyer DL; Doronina SO; Siegall CB; Francisco JA; Senter PD; Wahl AF
    Clin Cancer Res; 2004 Dec; 10(23):7842-51. PubMed ID: 15585616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amplification of CD20 Cross-Linking in Rituximab-Resistant B-Lymphoma Cells Enhances Apoptosis Induction by Drug-Free Macromolecular Therapeutics.
    Li L; Yang J; Wang J; Kopeček J
    ACS Nano; 2018 Apr; 12(4):3658-3670. PubMed ID: 29595951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Drug-Antibody Ratio on Pharmacokinetics, Biodistribution, Efficacy, and Tolerability of Antibody-Maytansinoid Conjugates.
    Sun X; Ponte JF; Yoder NC; Laleau R; Coccia J; Lanieri L; Qiu Q; Wu R; Hong E; Bogalhas M; Wang L; Dong L; Setiady Y; Maloney EK; Ab O; Zhang X; Pinkas J; Keating TA; Chari R; Erickson HK; Lambert JM
    Bioconjug Chem; 2017 May; 28(5):1371-1381. PubMed ID: 28388844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody-drug conjugates for the treatment of B-cell non-Hodgkin's lymphoma and leukemia.
    Chu YW; Polson A
    Future Oncol; 2013 Mar; 9(3):355-68. PubMed ID: 23469971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction and characterization of an anti-CD20 mAb nanocomb with exceptionally excellent lymphoma-suppressing activity.
    Li HF; Wu C; Chen T; Zhang G; Zhao H; Ke CH; Xu Z
    Int J Nanomedicine; 2015; 10():4783-96. PubMed ID: 26257518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-Drug Conjugates (ADCs) Derived from Interchain Cysteine Cross-Linking Demonstrate Improved Homogeneity and Other Pharmacological Properties over Conventional Heterogeneous ADCs.
    Behrens CR; Ha EH; Chinn LL; Bowers S; Probst G; Fitch-Bruhns M; Monteon J; Valdiosera A; Bermudez A; Liao-Chan S; Wong T; Melnick J; Theunissen JW; Flory MR; Houser D; Venstrom K; Levashova Z; Sauer P; Migone TS; van der Horst EH; Halcomb RL; Jackson DY
    Mol Pharm; 2015 Nov; 12(11):3986-98. PubMed ID: 26393951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate.
    Griffiths GL; Mattes MJ; Stein R; Govindan SV; Horak ID; Hansen HJ; Goldenberg DM
    Clin Cancer Res; 2003 Dec; 9(17):6567-71. PubMed ID: 14695162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The preclinical discovery of rituximab for the treatment of non-Hodgkin's lymphoma.
    Smolewski P; Robak T
    Expert Opin Drug Discov; 2015 Jul; 10(7):791-808. PubMed ID: 26083358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab-mediated cell signaling and chemo/immuno-sensitization of drug-resistant B-NHL is independent of its Fc functions.
    Vega MI; Huerta-Yepez S; Martinez-Paniagua M; Martinez-Miguel B; Hernandez-Pando R; González-Bonilla CR; Chinn P; Hanna N; Hariharan K; Jazirehi AR; Bonavida B
    Clin Cancer Res; 2009 Nov; 15(21):6582-94. PubMed ID: 19861448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
    Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
    J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of rituximab with graphene oxide confers direct cytotoxicity for CD20-positive lymphoma cells.
    Luo C; Deng Z; Li L; Clayton F; Chen AL; Wei R; Miles R; Stephens DM; Glenn M; Wang X; Jensen PE; Chen X
    Oncotarget; 2016 Mar; 7(11):12806-22. PubMed ID: 26859679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.